NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 1 pharmaceutical company such as PHARMACOSMOS. It is marketed under 1 brand name, including MONOFERRIC. Available in 3 different strengths, such as 1GM/10ML (100MG/ML), 100MG/ML (100MG/ML), 500MG/5ML (100MG/ML), and administered through 1 route including SOLUTION;INTRAVENOUS.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"74065","ingredient":"FERRIC DERISOMALTOSE","trade_name":"MONOFERRIC","family_id":"9a90a4c1cae64349b271","publication_number":"US10414831B2","cleaned_patent_number":"10414831","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-03-25","publication_date":"2019-09-17","legal_status":"Granted"} | US10414831B2 Molecular Formulation | 17 Sep, 2019 | Granted | 25 Mar, 2029 | |
| {"application_id":"74069","ingredient":"FERRIC DERISOMALTOSE","trade_name":"MONOFERRIC","family_id":"9a90a4c1cae64349b271","publication_number":"US11851504B2","cleaned_patent_number":"11851504","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-03-25","publication_date":"2023-12-26","legal_status":"Patented case"} | US11851504B2 Molecular Formulation | 26 Dec, 2023 | Patented case | 25 Mar, 2029 | |
| {"application_id":"74068","ingredient":"FERRIC DERISOMALTOSE","trade_name":"MONOFERRIC","family_id":"9a90a4c1cae64349b271","publication_number":"US12030962B2","cleaned_patent_number":"12030962","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-03-25","publication_date":"2024-07-09","legal_status":"Granted"} | US12030962B2 Molecular Formulation | 09 Jul, 2024 | Granted | 25 Mar, 2029 | |
| {"application_id":"74027","ingredient":"FERRIC DERISOMALTOSE","trade_name":"MONOFERRIC","family_id":"9a90a4c1cae64349b271","publication_number":"US8815301B2","cleaned_patent_number":"8815301","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-08-14","publication_date":"2014-08-26","legal_status":"Granted"} | US8815301B2 Molecular Formulation | 26 Aug, 2014 | Granted | 14 Aug, 2029 | |
| {"application_id":"115827","ingredient":"FERRIC DERISOMALTOSE","trade_name":"MONOFERRIC","family_id":"7438785a52994a07ae11","publication_number":"US11633489B2","cleaned_patent_number":"11633489","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-06-22","publication_date":"2023-04-25","legal_status":"Granted"} | US11633489B2 | 25 Apr, 2023 | Granted | 22 Jun, 2036 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Ferric Derisomaltose
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.